Submissions for variant NM_007294.4(BRCA1):c.1674del (p.Gly559fs)

dbSNP: rs80357600

Total submissions: 20

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)	RCV000031006	SCV000299634	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 1	2016-09-08	reviewed by expert panel	curation	Variant allele predicted to encode a truncated non-functional protein.
Labcorp Genetics (formerly Invitae), Labcorp	RCV000047556	SCV000075569	pathogenic	Hereditary breast ovarian cancer syndrome	2025-02-02	criteria provided, single submitter	clinical testing	This sequence change creates a premature translational stop signal (p.Gly559Valfs*13) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with breast and/or ovarian cancer (PMID: 9145677, 11773283, 23479189, 23683081). This variant is also known as 1790delA and 1793delA. ClinVar contains an entry for this variant (Variation ID: 37425). For these reasons, this variant has been classified as Pathogenic.
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge	RCV000031006	SCV000325121	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 1	2015-10-02	criteria provided, single submitter	clinical testing
Baylor Genetics	RCV000470654	SCV000540950	pathogenic	Familial cancer of breast	2017-02-23	criteria provided, single submitter	clinical testing
GeneDx	RCV000486975	SCV000568426	pathogenic	not provided	2023-07-13	criteria provided, single submitter	clinical testing	Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Reported in association with hereditary breast and ovarian cancer (Geisler et al., 2002; Dworkin et al., 2009; Rodriguez et al., 2012; Blay et al., 2013; de Juan Jimenez et al., 2013); Not observed at significant frequency in large population cohorts (gnomAD); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Also known as 1793delA; This variant is associated with the following publications: (PMID: 31921681, 11304778, 11773283, 31825140, 34413315, 23683081, 23479189, 9145677, 19340607, 22044689, 16267036, 28024868, 29659587, 28528518, 29752822)
Quest Diagnostics Nichols Institute San Juan Capistrano	RCV000486975	SCV000600261	pathogenic	not provided	2021-03-11	criteria provided, single submitter	clinical testing	This frameshift variant causes the premature termination of BRCA1 protein synthesis. In addition, it has been identified in individuals with breast cancer and ovarian cancer in the published literature (PMID: 31921681 (2019), 29446198 (2018), 28680148 (2017), 22044689 (2012), 11773283 (2002), 9145677 (1997)). Based on the available information, this variant is classified as pathogenic.
Color Diagnostics, LLC DBA Color Health	RCV000580485	SCV000682976	pathogenic	Hereditary cancer-predisposing syndrome	2020-11-16	criteria provided, single submitter	clinical testing	This variant deletes 1 nucleotide in exon 10 of the BRCA1 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in individuals affected with breast and ovarian cancer (PMID: 11773283, 23479189, 23683081, 28680148, 28528518). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Counsyl	RCV000031006	SCV000785551	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 1	2017-11-14	criteria provided, single submitter	clinical testing
Ambry Genetics	RCV000580485	SCV001173079	pathogenic	Hereditary cancer-predisposing syndrome	2024-04-02	criteria provided, single submitter	clinical testing	The c.1674delA pathogenic mutation, located in coding exon 9 of the BRCA1 gene, results from a deletion of one nucleotide at nucleotide position 1674, causing a translational frameshift with a predicted alternate stop codon (p.G559Vfs*13). This mutation has been reported in patients with personal and/or family histories suspicious for Hereditary Breast and Ovarian Cancer (Couch FJ et al. N. Engl. J. Med. 1997 May;336:1409-15; Geisler JP et al. J Natl Cancer Inst, 2002 Jan;94:61-7; Shih HA et al. J Clin Oncol, 2002 Feb;20:994-9; Dworkin AM et al. Fam Cancer, 2009 Apr;8:339-46; Rodríguez AO et al. Gynecol Oncol, 2012 Feb;124:236-43; Blay P et al. BMC Cancer. 2013 May;13:243; de Juan Jiménez I et al. Fam Cancer, 2013 Dec;12:767-77; Briceño-Balcázar I et al. Colomb Med (Cali), 2017 Jun;48:58-63; Torres D et al. Sci Rep, 2017 07;7:4713 Cock-Rada AM et al. Fam Cancer, 2018 01;17:23-30; Rebbeck TR et al. Hum Mutat, 2018 05;39:593-620; Wei H et al. Oncol Lett, 2018 Jun;15:9420-9428; Li JY et al. Int J Cancer, 2019 01;144:281-289; Oliver J et al. Front Oncol, 2019 Dec;9:1429). Of note, this alteration has also been reported as 1790delA and 1793delA in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV000047556	SCV001361785	pathogenic	Hereditary breast ovarian cancer syndrome	2019-08-09	criteria provided, single submitter	clinical testing	Variant summary: BRCA1 c.1674delA (p.Gly559ValfsX13) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 250426 control chromosomes (gnomAD). c.1674delA has been reported in the literature in multiple individuals affected with Hereditary Breast and Ovarian Cancer (Rebbeck_2018). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Eight ClinVar submissions (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Revvity Omics, Revvity	RCV000486975	SCV002017906	pathogenic	not provided	2019-10-03	criteria provided, single submitter	clinical testing
AiLife Diagnostics, AiLife Diagnostics	RCV000486975	SCV002502698	pathogenic	not provided	2021-06-03	criteria provided, single submitter	clinical testing
Molecular Genetics and NGS Laboratory, Hospital Fundacion Valle Del Lili	RCV003389314	SCV004101392	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 1; Pancreatic cancer, susceptibility to, 4; Fanconi anemia, complementation group S	2023-11-07	criteria provided, single submitter	clinical testing
Baylor Genetics	RCV000031006	SCV004215113	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 1	2024-02-03	criteria provided, single submitter	clinical testing
Mayo Clinic Laboratories, Mayo Clinic	RCV000486975	SCV005413237	pathogenic	not provided	2024-07-23	criteria provided, single submitter	clinical testing	PM2, PM5_strong, PVS1
Sharing Clinical Reports Project (SCRP)	RCV000031006	SCV000053599	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 1	2010-07-16	no assertion criteria provided	clinical testing
Breast Cancer Information Core (BIC) (BRCA1)	RCV000031006	SCV000144153	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 1	2002-05-29	no assertion criteria provided	clinical testing
Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto	RCV000047556	SCV000587156	pathogenic	Hereditary breast ovarian cancer syndrome	2014-01-31	no assertion criteria provided	research
Department of Pathology and Laboratory Medicine, Sinai Health System	RCV000486975	SCV001550743	pathogenic	not provided		no assertion criteria provided	clinical testing	The BRCA1 p.Gly559Valfs*13 variant was identified in 5 of 5020 proband chromosomes (frequency: 0.001) from individuals or families with non-hereditary diffuse gastric cancer, breast or ovarian cancer and was not identified in 2340 chromosomes from population-matched controls (Blay 2013, Couch 1997, de Juan Jimenez 2013, Sahasrabudhe 2017, Torres 2017). The variant was also identified in dbSNP (ID: rs80357600) as "With Pathogenic allele", ClinVar (classified as pathogenic by Invitae, GeneDx, and nine other submitters), COGR (1x pathogenic), LOVD 3.0 (6x pathogenic), BIC Database (6x with clinical importance), and in ARUP Laboratories database (definitely pathogenic). The variant was not identified in Cosmic, UMD-LSDB, or Zhejiang University databases. The variant was not identified in the following control databases: the Exome Aggregation Consortium (August 8th 2016) or the Genome Aggregation Database (Feb 27, 2017). The c.1674del variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 559 and leads to a premature stop codon at position 571. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the BRCA1 gene are an established mechanism of disease in hereditary breast and ovarian cancer (HBOC) syndrome and is the type of variant expected to cause the disorder. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic.
Molecular Oncology, Hospital Universitario Central de Asturias (HUCA)	RCV000031006	SCV005061278	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 1	2021-05-24	no assertion criteria provided	case-control